Compare Tilray Brands Inc (TLRY) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Tilray Brands Inc trades at $3.51 (market cap $530.54M), while iShares Broad USD Investment Grade Corporate Bond trades at $48.72 (market cap $17.53B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 33× Tilray Brands Inc's market cap, and Tilray Brands Inc is more actively traded (9,099,075 versus 4,695,583). Which is the better fit depends on your goals — on Pluang, investors hold Tilray Brands Inc for 31 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| TLRY | USIG | |
|---|---|---|
Market Cap | $530.54M | $17.53B |
Volume | 9,099,075 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $21.00 | $52.69 |
52-Week Low | $3.57 | $48.54 |
Typical Hold Time | 31 Days | 44 Days |
Enterprise Value | $684.46M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
USIG trades at $48.68 with minimal daily movement (+0.06%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces resistance at $49 with support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9% in Q2 2026.
The outlook remains cautious due to bearish technicals and lack of fundamental data. Investment opportunities include institutional accumulation, but risks involve market volatility and absence of recent financial disclosures. Investors should await updated earnings reports for clearer valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
